title: Nanomedicine and therapy of lung diseases.
abstract: The use of nanotechnology has significantly increased in different fields of science, including the development of drug delivery systems. Currently, the most modern pharmaceutical nanocarriers, such as liposomes, micelles, nanoemulsions and polymeric nanoparticles, demonstrate extremely useful properties from the point of view of drug therapy. In this context, the development of nanocarriers for pulmonary application has been much debated by the scientific community in recent decades. Although research on the use of nanoparticles for pulmonary application are still in the initial phase, the studies conducted to date suggest that the development of drug delivery systems for systemic or local treatment of diseases that affect the respiratory system may be promising.
authors: Faculdade de Medicina Nova Esperança, João Pessoa, PB, Brazil.
authors: Fabrício de Melo
authors: Fde M
authors: Garcia
mesh_terms: D016503:Drug Delivery Systems / Q000592:standards; D006801:Humans; D008171:Lung Diseases / Q000628:therapy*; D050997:Nanomedicine / Q000639:trends*; D053758:Nanoparticles / Q000627:therapeutic use*
references: Eur J Pharm Biopharm. 2014 Jan;86(1):7-22
references: 24007657
references: Int J Pharm. 2008 May 22;356(1-2):239-47
references: 18358652
references: Tuberculosis (Edinb). 2005 Jul;85(4):227-34
references: 15922668
references: Adv Drug Deliv Rev. 2006 Dec 1;58(14):1532-55
references: 17092599
references: PLoS One. 2012;7(10):e47453
references: 23082168
references: Nat Rev Drug Discov. 2005 Feb;4(2):145-60
references: 15688077
references: Adv Drug Deliv Rev. 2008 May 22;60(8):863-75
references: 18308418
references: Adv Drug Deliv Rev. 2011 May 30;63(6):441-55
references: 21118707